ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · IEX Real-Time Price · USD
9.21
+0.15 (1.66%)
May 17, 2024, 4:00 PM EDT - Market closed

ADMA Biologics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2011
Cash & Equivalents
51.3586.5251.0955.9226.75
Upgrade
Cash & Cash Equivalents
51.3586.5251.0955.9226.75
Upgrade
Cash Growth
-40.65%69.36%-8.64%109.03%-0.01%
Upgrade
Receivables
27.4215.5128.5813.243.47
Upgrade
Inventory
172.91163.28124.7281.5453.06
Upgrade
Other Current Assets
5.335.14.343.052.53
Upgrade
Total Current Assets
257.01270.4208.73153.7485.82
Upgrade
Property, Plant & Equipment
63.4768.7558.245.8532.99
Upgrade
Goodwill and Intangibles
4.034.545.265.976.69
Upgrade
Other Long-Term Assets
4.674.774.072.111.6
Upgrade
Total Long-Term Assets
72.1778.0667.5253.9341.27
Upgrade
Total Assets
329.18348.46276.25207.67127.09
Upgrade
Accounts Payable
15.6613.2312.4311.079.17
Upgrade
Deferred Revenue
1.871.982.122.262.4
Upgrade
Current Debt
1.050.910.590.370.23
Upgrade
Other Current Liabilities
31.2323.1615.246.252.22
Upgrade
Total Current Liabilities
49.8139.2730.3819.9514.03
Upgrade
Long-Term Debt
130.59142.8394.8792.9783.2
Upgrade
Other Long-Term Liabilities
13.5814.399.846.513.67
Upgrade
Total Long-Term Liabilities
144.17157.22104.799.4886.87
Upgrade
Total Liabilities
193.98196.49135.08119.42100.9
Upgrade
Total Debt
131.64143.7495.4693.3383.43
Upgrade
Debt Growth
-8.42%50.58%2.27%11.87%89.16%
Upgrade
Retained Earnings
-506.26-478.02-412.11-340.47-264.72
Upgrade
Shareholders' Equity
135.21151.97141.1788.2526.19
Upgrade
Net Cash / Debt
-80.29-57.22-44.37-37.41-56.68
Upgrade
Net Cash Per Share
-0.36-0.29-0.32-0.43-1.04
Upgrade
Working Capital
207.21231.14178.35133.7971.79
Upgrade
Book Value Per Share
0.600.771.011.020.48
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).